Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of CMAB007 vs Xolair in Healthy Subjects
NCT04778137Phase 1Completed
- Sponsor
- Taizhou Mabtech Pharmaceutical
- Start
- Dec 2020
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of omalizumab in asthma (2 arms), sponsored by Taizhou Mabtech Pharmaceutical. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity and Maximum Plasma Concentration. Started Dec 2020; status: completed.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04778137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04778137.